Contents

Introductions........................................................................................................................................... xix

Contributors............................................................................................................................................ xxii

Notice......................................................................................................................................................... xxiii

Chapter 1 The Theory and Definitions of Drug Safety (Pharmacovigilance).............................................. 1
The Theory.................................................................................................................................................. 1
  Adverse Event—ICH................................................................................................................................. 1
  Adverse Event/Adverse Experience—EMA.............................................................................................. 1
  Adverse Experience/Event—FDA........................................................................................................... 2
  Adverse Reaction..................................................................................................................................... 2
  Serious Adverse Event and Serious Adverse Reaction........................................................................... 2
  Nonserious.............................................................................................................................................. 3
  Suspected Adverse Drug Reaction (SADR)............................................................................................ 3
  Serious, Unexpected, Adverse Drug Reaction....................................................................................... 3
  Serious, Expected, Adverse Drug Reaction........................................................................................... 3
  Suspected Adverse Reaction—FDA.......................................................................................................... 3
  Suspected, Unexpected, Serious Adverse
  (Drug) Reaction (SUSAR)—EMA......................................................................................................... 3
  Unexpected—FDA.................................................................................................................................... 3
  Unexpected Adverse Reaction—EMA..................................................................................................... 4
  Unlisted Adverse Reaction—EMA.......................................................................................................... 4
  Expected.................................................................................................................................................. 4

The Practice............................................................................................................................................... 4
# Contents

## Chapter 2
Clinical Trials, Clinical Research Organizations, Phases I–IV, and Investigator-Initiated Trials ........................................... 7

- Phase I ............................................................................... 7
- Phase II .............................................................................. 8
- Phase III ............................................................................ 8
- Phase IV ............................................................................ 9
- Late Phase Studies .............................................................. 9
- Investigator-Initiated Trials or Studies ................................. 10
- Other Study Related Issues .................................................. 10
- Frequently Asked Questions ................................................ 12

## Chapter 3
Spontaneous Postmarketing Adverse Events .................................. 15

- United States Regulations .................................................. 18
- European Union Requirements ............................................. 18
- Other Regions ..................................................................... 18
- Process Issues ..................................................................... 19
- Frequently Asked Questions ................................................ 20

## Chapter 4
The Theory of Drug Safety (Pharmacovigilance) .............................. 21

- A Brief History of the FDA ................................................... 21
- Regulations, Laws, and Guidances ......................................... 22
- The United States Regulations and Guidances ......................... 22
- The European Union Directives, Regulations, and Guidances ... 23
- Frequently Asked Questions ................................................ 25

## Chapter 5
Adverse Events with New Chemical Entities, Generics, Excipients, Placebos, and Counterfeits ......................................................... 27

- Generics ............................................................................ 28
- Excipients .......................................................................... 28
- Placebo .............................................................................. 29
- Other Manufacturers’ Drugs’ AEs ............................................ 30
- Placebo and Breaking the Blind in Clinical Trials ...................... 30
- Picking up AEs due to Excipients ........................................... 31
- Generics ............................................................................ 31
- Adverse Events with Counterfeit, Impure, and Other Nonstandard Products ......................................................... 32
- Frequently Asked Questions ................................................ 33

## Chapter 6
Acute and Chronic (Late Occurring) Adverse Events, Adverse Events That Disappear (Bendectin), and Diethylstilbestrol .......................... 35

- Bendectin: A False Alert ....................................................... 36
  - Market Removal .............................................................. 36
  - Return to the Market in Canada and Europe ......................... 36
- Adriamycin ......................................................................... 36
- Gene Therapy ...................................................................... 36
- Antiretroviral Drugs ............................................................ 37
- Diethylstilbestrol (DES) ......................................................... 37
  - Delayed Onset of Malignancy (Long Latency) ....................... 37
  - Actions Taken .................................................................. 38
- The Future for Long-Latency AEs ........................................... 38
- Frequently Asked Questions ................................................ 38
<table>
<thead>
<tr>
<th>Chapter 7</th>
<th>The Mathematics of Adverse Events and a Brief Note on Pharmacoepidemiology</th>
<th>39</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weber Effect</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Secular Effects</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Reporting Rates Versus Incidence Rates</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Proportional Reporting Rate (PRR), Also Known As Disproportionality</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>Other Data Mining Methods</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Pharmacoepidemiology and Trials</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>Randomized Clinical Trial or Study</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>Case-Control Study</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Cohort Study</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Nested Case-Control Study</td>
<td>44</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 8</th>
<th>Where Data Reside</th>
<th>45</th>
</tr>
</thead>
<tbody>
<tr>
<td>AERS</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Clinical Trial Data</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>The Uppsala Monitoring Centre (UMC)</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>Vigibase</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>EMEA EudraVigilance Database</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Motherisk</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Health Canada</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>MHRA</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Teratology Data</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>General Practice Research Database (GPRD)</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Other Registries and Databases</td>
<td>48</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 9</th>
<th>Regulations, Directives, Guidances, and Laws</th>
<th>49</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td>European Union</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>The Practice</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Over-the-Counter Drugs</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>United States</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>European Union</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>Staying Up to Date</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>Scientific/Medical Literature</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>Meetings and Conferences</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>The Internet</td>
<td>53</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 10</th>
<th>Children, Elderly, and Other Special (Vulnerable) Groups</th>
<th>55</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>The Theory</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>In the United States</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>In the European Union</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>The Elderly</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>The ICH and FDA Guideline</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>FDA Guideline and Rule</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Other Special Groups</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>African Americans</td>
<td>59</td>
<td></td>
</tr>
</tbody>
</table>
Contents

Chapter 11  Drug Interactions .................................................. 61
Cytochrome P450 ............................................................... 62
Frequency ................................................................. 63
Communication ............................................................. 63

Chapter 12  AE Volume, Quality, Good Documentation Procedures, and
            Medical Records ...................................................... 65
Archiving ................................................................. 67
Record Retention Times ................................................. 68
Good Documentation Practices ....................................... 68

Chapter 13  Seriousness, Expectedness, and Causality ................. 69
Seriousness ................................................................. 69
Expectedness ............................................................... 71
Relatedness (Causality) ................................................. 72
Methodology ............................................................... 73
   Global Introspection .................................................. 73
   Algorithms .............................................................. 74
Comment ................................................................. 74
Health Authority Guidance and Requirements ..................... 74
United States FDA ......................................................... 75
European Union ......................................................... 76
CIOMS I Assessment of Causality .................................... 76
Uppsala Monitoring Centre (WHO) ................................... 77
   Judgment of Cases When Received Versus at the Time of
   Periodic Reporting and Signaling .................................. 77
Comment ................................................................. 77

Chapter 14  Coding of AEs and Drug Names ............................. 79
AE Coding ................................................................. 79
   MedDRA ............................................................... 79
   Regulatory Status ..................................................... 80
   Standardized MedDRA Queries (SMQs) ......................... 82
   SNOMED CT .......................................................... 82
AE Severity Coding ...................................................... 83
Drug Names and Drug Dictionaries ................................... 83
Multiple Names and Name Changes ................................ 84
WHO Drug Dictionary Enhanced .................................... 85
EudraVigilance Medicinal Product Dictionary (EVMPD) ....... 86
The Future ................................................................. 86

Chapter 15  Expedited and Aggregate Reporting in Clinical Trials .... 87
Expedited Reporting ..................................................... 87
Clinical Trial Reporting ................................................ 87
United States Requirement for Expedited IND Reports ........ 88
Expedited IND Reports (Alert Reports, 7- and 15-Day IND Reports) ......................................................... 88
IND Annual Reports ..................................................... 90
Other Clinical Trial (IND) Reporting Issues ....................... 91
When to Start Collecting Serious AEs in Trial .................... 92
European Union Requirements ....................................... 92
   Expedited Reporting in Clinical Trials ........................ 92
### Annual Safety Reports (ASR)
- Canadian Requirements .................................................. 93
- Elsewhere ............................................................................. 94

### Chapter 16: Postmarketing Spontaneous ICSR/SAE Reporting
- General Principles ............................................................... 95
- Postmarketing ICSRs Versus Clinical Trial ICSRs .................. 95
- Sources of AEs ...................................................................... 97
- Literature and Publications ................................................. 98
- Other Sources of Reports .................................................... 98
- Follow-Up .......................................................................... 98
- Notes on United States Requirements for Postmarketing
  - NDA Reporting of SAEs ................................................... 99
  - MedWatch to Manufacturer Program ............................... 99
  - Reports from the FDA via the Freedom of Information Act 100
  - Instructions on Filling Out the MedWatch Form ................. 100
  - European Union Regulations ......................................... 100
  - Canadian Regulations ..................................................... 101
  - Australian Regulations ................................................... 101
  - Frequently Asked Questions ............................................ 101

### Chapter 17: Periodic Adverse Drug Experience Reports (PADERS):
- NDA Periodic Reports and Periodic Safety Update Reports (PSURs) 103
- NDA Periodic Reports ........................................................ 103
- PSURs to the FDA ............................................................... 104
  Postmarketing Periodic Reports .........................................
  - Section 1: Narrative Summary and Analysis ...................... 105
  - Section 2: Narrative Discussion of Actions Taken ............. 105
  - Section 3: Index Line Listing ............................................ 106
  - Section 4: FDA Form 3500As or VAERS Forms ................. 106
- Other Reports ..................................................................... 106
- PSURs .............................................................................. 106
  - PSURs to the FDA .......................................................... 108
- Frequently Asked Questions ............................................. 108

### Chapter 18: Epidemiology and Pharmacoepidemiology: What Are They?
- What Are Their Limitations and Advantages? ...................... 109
- Case Report or Individual Case Safety Report (ICSR) ............ 110
- Aggregate Reports ............................................................. 110
- Randomized Clinical Trial (RCT) ........................................ 111
- Case-Control Study ........................................................... 111
- Cohort Study ..................................................................... 112
- Nested Case-Control Study ............................................... 113
- Confidence Intervals .......................................................... 113
- Frequently Asked Questions ............................................. 113

### Chapter 19: Signals and Signaling in the Context of Risk Management
- The Signal ......................................................................... 115
- Signal Sources and Generation .......................................... 116
- Increased Frequency ............................................................ 117
- Data Mining ........................................................................ 117
### Contents

**Chapter 20**  
Information Technology, Databases, and Computers  
Required Safety Database Functionality  
Database Support  
Data Entry  
Data Transmission (E2B)  
The Future of E2B (R3)  
Safety Databases  
Database Migration  
Health Level 7 (HL-7)  
CDISC  
Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT)

**Chapter 21**  
The United States Food and Drug Administration (FDA) and MedWatch  
CDER (Center for Drug Evaluation and Research)  
The Safety Portal  
Risk Management  
MedWatch  
Safety Databases  
Other Useful FDA Web Pages  
CBER (Center for Biologics Evaluation and Research)  
CDRH (Center for Devices and Radiologic Health)  
OTCs (Over-the-Counter Products)  
Drug Safety Oversight Board  
Prescription Drug User Fee Act (PDUFA) and FDAAA  
Prescription Drug User Fee Act Five-Year Plan  
Sentinel Initiative  
The Tome  
What Is Expected from Drug Companies by the FDA  
What Is Expected from Consumers and Healthcare Professionals by the FDA  
FDA Publications and Updates  
Drug Safety Inspections  
Frequently Asked Questions.
<table>
<thead>
<tr>
<th>Chapter 22</th>
<th>The European Medicines Agency (EMA, EMEA)</th>
<th>151</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume 9A Postmarketing PV</td>
<td>153</td>
<td></td>
</tr>
<tr>
<td>Volume 10 Clinical Trial PV</td>
<td>154</td>
<td></td>
</tr>
<tr>
<td>The EMA Website</td>
<td>154</td>
<td></td>
</tr>
<tr>
<td>European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP)</td>
<td>154</td>
<td></td>
</tr>
<tr>
<td>Newsletters and RSS Feeds</td>
<td>155</td>
<td></td>
</tr>
<tr>
<td>Comments</td>
<td>155</td>
<td></td>
</tr>
<tr>
<td>Future Changes</td>
<td>155</td>
<td></td>
</tr>
<tr>
<td>Premarking</td>
<td>155</td>
<td></td>
</tr>
<tr>
<td>Postmarking</td>
<td>156</td>
<td></td>
</tr>
<tr>
<td>Frequently Asked Questions</td>
<td>156</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 23</th>
<th>The Qualified Person for Pharmacovigilance</th>
<th>159</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practicalities</td>
<td>160</td>
<td></td>
</tr>
<tr>
<td>Frequent QP Inspection Findings by the EMA</td>
<td>161</td>
<td></td>
</tr>
<tr>
<td>Frequently Asked Questions</td>
<td>161</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 24</th>
<th>United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA)</th>
<th>163</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Yellow Card Scheme</td>
<td>164</td>
<td></td>
</tr>
<tr>
<td>Black Triangle Products [▲]</td>
<td>164</td>
<td></td>
</tr>
<tr>
<td>Regulations</td>
<td>164</td>
<td></td>
</tr>
<tr>
<td>Inspections</td>
<td>165</td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Industry Page: A One-Stop Resource</td>
<td>165</td>
<td></td>
</tr>
<tr>
<td>Drug Analysis Prints (DAPs)</td>
<td>165</td>
<td></td>
</tr>
<tr>
<td>Providing SAE Cases to MA Holders</td>
<td>166</td>
<td></td>
</tr>
<tr>
<td>E-mail Alerting Service</td>
<td>166</td>
<td></td>
</tr>
<tr>
<td>Reporting AEs in the United Kingdom</td>
<td>166</td>
<td></td>
</tr>
<tr>
<td>Good Pharmacovigilance Practice Guide Publication (&quot;The Purple Book&quot;)</td>
<td>166</td>
<td></td>
</tr>
<tr>
<td>Comments</td>
<td>166</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 25</th>
<th>Health Canada/Santé Canada</th>
<th>167</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-mail Notifications and RSS Feeds</td>
<td>168</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 26</th>
<th>Australian Therapeutic Goods Administration (TGA)</th>
<th>169</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE Reporting</td>
<td>169</td>
<td></td>
</tr>
<tr>
<td>Risk Management</td>
<td>170</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 27</th>
<th>The Uppsala Monitoring Centre</th>
<th>171</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO Programme for International Drug Monitoring</td>
<td>171</td>
<td></td>
</tr>
<tr>
<td>Publications</td>
<td>172</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 28</th>
<th>Data Privacy and Security</th>
<th>173</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States Health Insurance Portability and Accountability Act (HIPAA)</td>
<td>174</td>
<td></td>
</tr>
<tr>
<td>The European Union and the Privacy Directive</td>
<td>175</td>
<td></td>
</tr>
<tr>
<td>Safe Harbor</td>
<td>176</td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>177</td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>178</td>
<td></td>
</tr>
</tbody>
</table>
Chapter 29  The Roles and Interactions of Companies, Governments, Nongovernmental Organizations (NGOs), and Others in the World of Pharmacovigilance

- The Pharmaceutical Companies
- Governments
- The Media
- NGOs and Lobbies
- Industry Organizations
- Litigation, Lawyers, and Legalities
- Other Groups
- Organizations for Drug Safety Personnel
- Conclusions and Comments
- Frequently Asked Questions

Chapter 30  Risk: What Is It? Risk Management and Assessment, Risk Evaluation and Minimization Systems (REMS), and Risk Management Plans (RMPs)

- Why Risk Management?
- The FDA
- The Proposed REMS
- Comments
- Classwide REMS
  - REMS Template
  - Comments
- European Union Risk Management Plans (RMPs)
- When Is an RMP Needed?
- The Safety Specification (Part I)
  - The Nonclinical Section
- The Clinical Section
- The PV Plan
- Practicalities, Coordination, and Other Comments
- Risk Management Within Pharma Companies
- Comments and Suggestions

Chapter 31  The United States FDA’s Three Risk Guidances of 2005

- The First Guidance: Premarketing Risk Assessment
  - Size of the Safety Database
  - Long-Term Controlled Safety Trials
  - Diversity
  - Exploring Dose Effects
  - Drug Interactions
  - Comparative Safety Data
  - Large Simple Safety Studies
  - Medication Errors
  - Assessing Safety During Product Development
  - Data Analysis and Interpretation
- The Second Guidance: Development and Use of Risk Minimization Action Plans
- The Third Guidance: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment
  - Identifying Signals: Good Reporting Practice
  - Developing a Case Series
  - Data Mining
<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CIOMS V (2001): Current Challenges in Pharmacovigilance:</strong></td>
<td></td>
</tr>
<tr>
<td>Pragmatic Approaches.</td>
<td>239</td>
</tr>
<tr>
<td>CIOMS VI (2005): Management of Safety Information from Clinical Trials</td>
<td>244</td>
</tr>
<tr>
<td>General Principles and Ethical Considerations.</td>
<td>244</td>
</tr>
<tr>
<td>Systemic Approach to Managing Safety Data</td>
<td>244</td>
</tr>
<tr>
<td>Data Collection and Management</td>
<td>245</td>
</tr>
<tr>
<td>Other Points</td>
<td>245</td>
</tr>
<tr>
<td>Risk Identification and Evaluation</td>
<td>246</td>
</tr>
<tr>
<td>Frequency of Review of Safety Information</td>
<td>246</td>
</tr>
<tr>
<td>Analysis and Evaluation</td>
<td>247</td>
</tr>
<tr>
<td>Statistical Approaches</td>
<td>247</td>
</tr>
<tr>
<td>Regulatory Reporting and Communications of Safety Information from Clinical Trials</td>
<td>247</td>
</tr>
<tr>
<td>CIOMS VIII (2010): Signal Detection (Points to Consider in Application of Signal Detection in Pharmacovigilance)</td>
<td>249</td>
</tr>
<tr>
<td>Other Areas</td>
<td>249</td>
</tr>
</tbody>
</table>

**Chapter 37**

International Conference on Harmonization (ICH) ........................................ 251

E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting ........................................ 251

- Definitions ......................................................................................... 252
- What Should Be Reported to Regulatory Authorities as Expedited Reports? 252
- Reporting Time Frames ...................................................................... 252
- Minimum Criteria for Reporting ......................................................... 252
- Managing Blinded Cases ..................................................................... 253
- Other Issues ....................................................................................... 253

The E2B(R2) and M2 Documents .................................................................. 253

E2C(R1) Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs ....................................... 254

E2D: Postapproval Safety Data Management: Definitions and Standards for Expedited Reporting ....................................... 258

- Definitions ......................................................................................... 258
- Sources of Individual Case Safety Reports ........................................ 259
- Standards for Expedited Reporting ................................................... 260
- Good Case Management Practices ....................................................... 260

E2E: Pharmacovigilance Planning .............................................................. 261

- Background and Scope ........................................................................ 262
- The Sections of a Pharmacovigilance Plan ......................................... 262
- Pharmacovigilance Plan ...................................................................... 263

E2F: Development Safety Update Report ................................................... 264

**Chapter 38**

Pharmaceutical Companies ........................................................................ 267

- Big and Somewhat Big Pharma ............................................................ 267
- Midsized and Small Pharma .................................................................. 269

Clinical Research Organizations, Also Called Contract Research Organizations (CRO) ........................................ 269

Mergers, Acquisitions, and Bankruptcies ............................................... 270

**Chapter 39**

Universities and Academic Medical Centers ........................................... 271

- The Bayh-Dole Act in the United States ............................................ 271
- Clinical Research Units ....................................................................... 272
### Chapter 40

**Organization of a Typical Drug Safety Department**

- Management ................................................. 275
- The Qualified Person ...................................... 275
- Triage Unit ................................................. 275
- Case Assessment and Prioritization ...................... 276
- Data Entry Unit .............................................. 276
- Case Processing Unit ...................................... 277
- Medical Case Review ....................................... 277
- Transmission Unit .......................................... 277
- Regulatory Unit ............................................. 277
- Legal Unit .................................................. 277
- Signaling, Pharmacovigilance, Pharmacoepidemiology,
  Medical Information, or Medical Affairs Unit .......... 277
- Aggregate Report Preparation ......................... 278
- Labeling Review and Update for Safety ................. 278
- Archive/File Room ......................................... 278
- Information Technology/Informatics Liaison .......... 279
- Standard Operating Procedure (SOP) Creation and Maintenance 279
- Training .................................................... 280
- Quality Assurance/Control ................................ 280
- Safety (AE) Exchange Agreement Function: Creation and Maintenance 280
- Literature Review ......................................... 281
- Data Dictionary Maintenance ............................ 281
- Coding Unit ............................................... 281
- Planning and Project Management/Operations .......... 282
- Risk Management .......................................... 282
- Liaison to External Organizations/Drug Safety Intelligence 282

### Chapter 41

**How an Individual Case Safety Report (ICSR) Is Handled from Start to Finish**

- AE Sources and Arrival in the Safety Department ........ 284
- Triage ...................................................... 286
- Database Entry ........................................... 287
- Quality Review ............................................ 288
- Follow-Up .................................................. 288
- Medical Review ........................................... 288
- Case Closure .............................................. 288
- Case Distribution and Transmission .................... 289
- Tracking .................................................... 289
- Investigator Notification ................................ 290
- 15 Calendar Days and Day 0 Versus Day 1 ............... 291

### Chapter 42

**The Safety Department's Role in Clinical Research, Marketing and Sales, Labeling, Regulatory, Due Diligence, and Legal Issues**

- Clinical Research ......................................... 293
- CROs ......................................................... 296
- Marketing and Sales ....................................... 296
- The Labeling Department ................................ 297
Contents xv

Chapter 48 Audits and Inspections ........................................... 329
The Basics ........................................................................ 329
Scope of the Audit ............................................................. 330
How an Inspection Flows ...................................................... 331
Findings ........................................................................ 332
Penalties ........................................................................ 332
Common Inspection Findings .............................................. 332
The Response to the Inspection of Audit ................................. 333
The Corrective Action Preventive Action Plan (CAPA) ............... 333
FDA Inspections ................................................................ 333
Comments on EMA and MHRA Inspections ............................ 334
Quality Systems and Inspection Preparation in Companies .......... 334
Key Documents ................................................................ 335
Summary and Comments ...................................................... 335

Chapter 49 Summary/Description of PV Systems and Risk-Based Inspections ........................................................................... 337
The Detailed Description of the PV System (Volume 9A Section 2.2) .................................................................................. 337
The MHRA Summary of PV Systems (SPS) ................................. 338
The Compliance Report (MHRA) .............................................. 340
Comment ........................................................................ 341

Chapter 50 Ethical Issues and Conflicts of Interest ........................ 343
Dynamics at Play in Regard to Drug Safety and Companies .......... 345
Data Safety Management Boards and Ethics Committees/IRBs ....... 347
Dynamics in Play in Regard to Drug Safety and Health Agencies .... 347
Dynamics in Play in Regard to Drug Safety and Academia and Nonacademic Healthcare Facilities ................................. 348
Dynamics in Play in Regard to Drug Safety and Consumer Groups, Disease Groups, and the Internet (Blogs, Websites, Social Media, etc.) .................................................. 349
Dynamics in Play in Regard to Drug Safety and Lawyers/Litigation .......................................................... 350
### Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codes of Conduct</td>
<td>350</td>
</tr>
<tr>
<td>Comments and Summary</td>
<td>350</td>
</tr>
<tr>
<td>Chapter 51 Vigilance of Natural Health Products</td>
<td>351</td>
</tr>
<tr>
<td>Mano Murty, MD, CCFP, FCFP, Kevin Bernardo, ND, BHSc,</td>
<td></td>
</tr>
<tr>
<td>and Alison Ingham, PhD</td>
<td></td>
</tr>
<tr>
<td>Prevalence of NHP Use and Safety Issues</td>
<td>352</td>
</tr>
<tr>
<td>Data Sources and Adverse Reaction Reporting (ARR)</td>
<td>352</td>
</tr>
<tr>
<td>ARs and Causality Assessment</td>
<td>353</td>
</tr>
<tr>
<td>Safe Analysis: Signal Evaluation</td>
<td>354</td>
</tr>
<tr>
<td>NHP Interactions and Medical Relevance</td>
<td>354</td>
</tr>
<tr>
<td>International Collaboration: Methods to Address Regulatory Diversity</td>
<td>354</td>
</tr>
<tr>
<td>Initiatives to Strengthen Vigilance of NHPs</td>
<td>354</td>
</tr>
<tr>
<td>Summary</td>
<td>357</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>358</td>
</tr>
<tr>
<td>References</td>
<td>358</td>
</tr>
<tr>
<td>Chapter 52 Real-World Issues: Fialuridine</td>
<td>361</td>
</tr>
<tr>
<td>Chapter 53 Real-World Issues: Fen-Phen</td>
<td>365</td>
</tr>
<tr>
<td>Chapter 54 Real-World Issues: Nomifensine</td>
<td>367</td>
</tr>
<tr>
<td>Web Resources</td>
<td>369</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>395</td>
</tr>
<tr>
<td>Index</td>
<td>399</td>
</tr>
</tbody>
</table>